TP53 and ovarian cancer: Our previous studies have demonstrated that a combination of low-dose DDP with gene therapy expressing tumor protein p53 (p53) and mouse double minute 2 homolog (MDM2) siRNA, delivered by attenuated Salmonella enterica serovar Typhi vaccine strain Ty21a (Salmonella Typhi Ty21a), synergistically inhibited ovarian cancer and PCa growth without damaging normal tissues22–25.